Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for palliative care
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on palliative care or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on palliative care and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Mattresses or Overlays Used in Palliative End-of-Life Care: Clinical Evidence and Guidelines Mattresses or Overlays Used in Palliative End-of-Life Care: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Mattresses or Overlays Used in Palliative End-of-Life Care: Clinical Evidence and Guidelines Mattresses or Overlays Used in Palliative End-of-Life Care: Clinical Evidence and Guidelines Last updated: January 30, 2019 Project Number: RB1304-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding patient comfort and satisfaction with mattresses or mattress overlays used in palliative end-of-life care? What are the evidence-based guidelines regarding the use of mattresses or mattress overlays in palliative end-of-life care? Key Message One non-randomized study and one evidence-based guideline were identified regarding the use of mattresses in palliative end-of-life care
, future projections and implications for services. BMC Med. 15(1), 102. 4 Bone AE, et al. (2018). What is the impact of population ageing on the future provision of end-of-life care? Population-based projections of place of death. Palliat. Med. 32(2), 329-336. 5 The Academy of Medical Sciences (2018). Multimorbidity: a priority for global health research. https://acmedsci.ac.uk/file-download/82222577 6 Murtagh FE, et al. (2013). How many people need palliativecare? A study developing and comparing (...) on the future provision of end-of-life care? Population-based projections of place of death. Palliat. Med. 32(2), 329-336. 10 Barnett K, et al. (2012). Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380(9836), 37-43. 11 Worldwide PalliativeCare Alliance and World Health Organisation (2014). Global Atlas of PalliativeCare at the End of Life. https://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf 12 Etkind SN, et al
Perinatal PalliativeCare Perinatal PalliativeCare - ACOG Menu ▼ Perinatal PalliativeCare Page Navigation ▼ Number 786 Committee on Obstetric Practice Committee on Ethics The American Academy of Pediatrics and the Society for Maternal-Fetal Medicine endorse this document. This Committee Opinion was developed by the Committee on Obstetric Practice with the assistance of committee member Russell S. Miller, MD and the American Academy of Pediatrics’ liaison member James J. Cummings, MD (...) ; and the Committee on Ethics with the assistance of the American Academy of Pediatrics’ liaison member Robert Macauley, MD and the Society for Maternal-Fetal Medicine’s liaison member Steven J. Ralston, MD, MPH. Perinatal PalliativeCare ABSTRACT : Perinatal palliativecare refers to a coordinated care strategy that comprises options for obstetric and newborn care that include a focus on maximizing quality of life and comfort for newborns with a variety of conditions considered to be life-limiting in early
Clinical Practice Guidelines for Quality PalliativeCare Clinical Practice Guidelines for Quality PalliativeCare | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies with the greatest impact on clinical care. Clinical Practice Guidelines (...) for Quality PalliativeCare The American Academy of Pediatrics has endorsed the following publication: National Coalition for Hospice and PalliativeCare, National Consensus Project. Clinical Practice Guidelines for Quality PalliativeCare . 4th ed. Richmond, VA: National Coalition for Hospice and PalliativeCare; 2018. Available at: . All statements of endorsement from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, retired, or revised at or before
Stereotactic ablative radiotherapy versus standard of carepalliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The oligometastatic paradigm suggests that some patients with a limited number of metastases might be cured if all lesions are eradicated. Evidence from randomised controlled trials to support this paradigm is scarce. We aimed to assess the effect of stereotactic ablative radiotherapy (SABR) on survival, oncological (...) ), we randomly assigned patients (1:2) to receive either palliative standard of care treatments alone (control group), or standard of care plus SABR to all metastatic lesions (SABR group), using a computer-generated randomisation list with permuted blocks of nine. Neither patients nor physicians were masked to treatment allocation. The primary endpoint was overall survival. We used a randomised phase 2 screening design with a two-sided α of 0·20 (wherein p<0·20 designates a positive trial). All
2019LancetControlled trial quality: predicted high
Would You Refer This Patient With Cancer to a PalliativeCare Specialist?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. In 2016, the American Society of Clinical Oncology published a guideline recommending that all patients with advanced cancer be referred to palliativecare providers. This recommendation was based on a series of trials showing that palliativecare, when added to standard oncology treatment, improves outcomes, including quality of life. Here, 2 oncologists (...) , 1 of whom is also a palliativecare specialist, debate the guideline and discuss how best to care for a 71-year-old woman with metastatic neuroendocrine carcinoma who has a short life expectancy but feels well and has no symptoms related to her cancer or chemotherapy.
Early specialist palliativecare on quality of life for malignant pleural mesothelioma: a randomised controlled trial Malignant pleural mesothelioma (MPM) has a high symptom burden and poor survival. Evidence from other cancer types suggests some benefit in health-related quality of life (HRQoL) with early specialist palliativecare (SPC) integrated with oncological services, but the certainty of evidence is low.We performed a multicentre, randomised, parallel group controlled trial comparing (...) early referral to SPC versus standard care across 19 hospital sites in the UK and one large site in Western Australia. Participants had newly diagnosed MPM; main carers were additionally recruited.review by SPC within 3 weeks of allocation and every 4 weeks throughout the study. HRQoL was assessed at baseline and every 4 weeks with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30.change in EORTC C30 Global Health Status 12 weeks after
Palliativecare - oral: Metronidazole Metronidazole | Prescribing information | Palliativecare - oral | CKS | NICE Search CKS… Menu Metronidazole Palliativecare - oral: Metronidazole Last revised in October 2018 Metronidazole Prescribing metronidazole Common adverse effects include a metallic taste and gastrointestinal irritation (in particular nausea and vomiting). These are more common at higher doses. Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal
Palliativecare - oral: History History | Diagnosis | Palliativecare - oral | CKS | NICE Search CKS… Menu History Palliativecare - oral: History Last revised in October 2018 History Enquiry into symptoms and problems with the oral cavity should be part of a full history and examination that includes physical, psychological, social, and spiritual issues: Enquire about dry mouth, oral pain, halitosis, alteration in taste, excessive salivation, bad breath, difficulty chewing, difficulty
Palliativecare - oral: Corticosteroids Corticosteroids | Prescribing information | Palliativecare - oral | CKS | NICE Search CKS… Menu Corticosteroids Palliativecare - oral: Corticosteroids Last revised in October 2018 Corticosteroids As corticosteroid use for aphthous ulcers is short-term, potential problems often associated with corticosteroid use (for example osteoporosis) are not relevant. Beclometasone spray or betamethasone soluble tablets are more potent than hydrocortisone lozenges
Palliativecare - oral: Examination Examination | Diagnosis | Palliativecare - oral | CKS | NICE Search CKS… Menu Examination Palliativecare - oral: Examination Last revised in October 2018 Examination The oral cavity examination should be part of a full examination of the person. Look for signs of dehydration and mouth breathing. Examine the mouth for evidence of: Dryness. Ulceration and vesicles (see ). Vesicles are very rarely see in the mouth as they rapidly burst. Erythema. White
Palliativecare - oral: Chlorhexidine Chlorhexidine | Prescribing information | Palliativecare - oral | CKS | NICE Search CKS… Menu Chlorhexidine Palliativecare - oral: Chlorhexidine Last revised in October 2018 Chlorhexidine Chlorhexidine is the most effective antiseptic gel/mouthwash for reducing plaque, gingivitis, and gingival bleeding [ ; ]. In the UK, products available for the prevention and treatment of gingivitis include chlorhexidine gluconate mouthwash (0.12% and 0.2%), spray (0.2
Palliativecare - oral: Antivirals Antivirals | Prescribing information | Palliativecare - oral | CKS | NICE Search CKS… Menu Antivirals Palliativecare - oral: Antivirals Last revised in October 2018 Antivirals Recommended antivirals Topical aciclovir and topical penciclovir are recommended in immunocompetent people who are in the early stages of an uncomplicated herpes simplex infection in the locality of the lips. Oral aciclovir is recommended in: Immunocompetent people who
Palliativecare - cough: Scenario: COVID-19 Management Scenario: COVID-19 | Management | Palliativecare - cough | CKS | NICE Search CKS… Menu Scenario: COVID-19 Palliativecare - cough: Scenario: COVID-19 Management Last revised in April 2020 Scenario: COVID-19 Management From birth onwards. How should my management vary when considering the possibility of COVID-19? Be aware that older people or those with comorbidities, frailty, impaired immunity or a reduced ability to cough and clear (...) issuing an 'acute' prescription with a limited supply. Advise the person of the risks of constipation and consider prescribing a regular stimulant laxative. Avoid cough suppressants in people who suffer from chronic bronchitis and bronchiectasis as this can cause sputum retention. Seek specialist advice for people aged under 18 years. Basis for recommendation These recommendations are based on the National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline: managing symptoms
Palliativecare - cough: Pholcodine linctus BP Pholcodine linctus BP | Prescribing information | Palliativecare - cough | CKS | NICE Search CKS… Menu Pholcodine linctus BP Palliativecare - cough: Pholcodine linctus BP Last revised in April 2020 Pholcodine linctus BP If the person is already taking a strong opioid such as morphine, do not try a weak opioid such as pholcodine. Instead an 'as required' dose of morphine solution should be used to relieve cough. Pholcodine Linctus BP 5 to 10 mg
Palliativecare - cough: Scenario: Assessment Scenario: Assessment | Management | Palliativecare - cough | CKS | NICE Search CKS… Menu Scenario: Assessment Palliativecare - cough: Scenario: Assessment Last revised in April 2020 Scenario: Assessment From age 16 years onwards. What should I ask about the cough? Ask about the: Impact on the person's quality of life. Severity, time of onset, and duration of the cough. Pattern and character of the cough, for example: Dry cough, persisting over (...) — large amounts (> 100 mL per day) are produced by people with bronchorrhoea, which can occur as a result of bronchiolo-alveolar cancer, asthma, or tuberculosis. Blood — haemoptysis from tumour, or tumour erosion. Dyspnoea — effusion, lung collapse, lymphangitis carcinomatosa. For more information on causes and management of dyspnoea, see the CKS topic on . Basis for recommendation These recommendations are based on expert opinion from palliativecare and medical literature developed from clinical
Palliativecare - cough: Nebulized sodium chloride Nebulized sodium chloride | Prescribing information | Palliativecare - cough | CKS | NICE Search CKS… Menu Nebulized sodium chloride Palliativecare - cough: Nebulized sodium chloride Last revised in April 2020 Nebulized sodium chloride When nebulized 0.9% saline solution is used to ease cough associated with tenacious secretions [ ; ; ]: Initially use 2.5 mL to 5 mL four times a day as needed and before physiotherapy [ ]. If greater
Palliativecare - cough: Mucolytics Mucolytics | Prescribing information | Palliativecare - cough | CKS | NICE Search CKS… Menu Mucolytics Palliativecare - cough: Mucolytics Last revised in April 2020 Mucolytics Carbocisteine and mecysteine hydrochloride are options to reduce the viscosity of the secretions. If a palliativecare patient does not demonstrate any convincing benefit after a week or two of using a mucolytic, then use of a mucolytic should be discontinued. For carbocisteine